PIK3CG and liposarcoma: For example, clinical trials of the PI3K inhibitor, ZSTK474, showed prolonged stable disease for sarcoma patients (Lockhart et al., 2013), and several groups have reported on the potential efficacy of PI3K inhibitors in sarcoma mouse and zebrafish models, such as BKM120 (Buparlisib) in undifferentiated pleomorphic sarcoma (Kim et al., 2012), and BEZ235 in well-differentiated liposarcoma (Gutierrez et al., 2011) and chondrosarcoma (Zhang et al., 2013).